Results 181 to 190 of about 23,778,628 (351)
Statistics and Experimental Design, by Norman L. Johnson and Fred C. Leone. John Wiley and Sons, Inc., New York, 1964. Vol. I, xiii + 523 pages, $10.95; Vol. II, ix + 399 pages, $11.50. [PDF]
H. Kaufman
openalex +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Machine learning for experimental design of ultrafast electron diffraction. [PDF]
Shaaban M, El-Borgi S, Krishnamoorthy A.
europepmc +1 more source
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau+9 more
wiley +1 more source
Ptychoscopy: a user friendly experimental design tool for ptychography. [PDF]
Skoupy R+5 more
europepmc +1 more source
THE EXPERIMENTAL DESIGN FOR BeO IRAADIATION EXPERIMENTS ORNL 41-8 AND ORNL 41-9
D. A. Gardiner
openalex +2 more sources
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp+13 more
wiley +1 more source
Optimizing nanomaterial dosages in concrete for structural applications using experimental design techniques. [PDF]
Dhairiyasamy R+3 more
europepmc +1 more source
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source